WORCESTER COUNTY, Md. – Worcester County has received extra money from state tax revenue on recreational cannabis sales. Officials plan to use the money to help those who need it most.
Commissioner Joe Mitrecic said it’ll help the areas that might go overlooked. “Really, it’s going to filter down to the municipalities. And it needs to be used for the community, it was designed to help out lower income communities.”
$1 million was given to Worcester County, and the county adopted laws outlining its use at a commissioner’s meeting in June. The vote was done unanimously, and according to Commissioner Mitrecic, officials already have ideas in mind.
“There is a project in Pocomoke to redo some sidewalks down there, and this would certainly fit into that.”
Non-profits, small businesses, and other means of community improvement can apply for funds. Ian Chenkin, the General Manager for Hi-Tide Dispensary in Ocean City, said this is a huge step forward.
“The fact the money will be going to new small businesses or community programs, we’re fully behind it, and we’ve always wanted to be a part of this community.”
However, funds can not be spent on law enforcement or other county programs. Commissioner Mitricic hope this piece of revenue will bring about balance.
“Folks that are incarcerated for possession of marijuana or distribution of marijuana tend to come from lower-income neighborhoods, so this is to help offset that.”
County officials will accept applications through the end of this summer, and the grants award will be announced in October.
Emergency regulations for Nebraska’s medical cannabis program have come under fire from the National Organization for the Reform of Marijuana Laws (NORML) and Nebraskans for Medical Marijuana (NMM).
Last week, the Nebraska Medical Cannabis Commission approved emergency regulations, which received the Governor Jim Pillen’s signoff this week. Among the rules is a ban on dispensaries selling raw plant material (botanical cannabis), smokeable and vapeable products, those containing flavouring or colouring, and edibles.
NORML says the Commission’s regulations represents a slap in the face to voters and bad public policy.
“Limiting patients’ options to solely cannabis-infused pills, tablets, lozenges, and other non-botanical formulations is not in their best interests,” said NORML Deputy Director Paul Armentano.
He said the regulations will encourage patients to obtain products from the illicit market.
“This undermines one of the primary goals of the voter-approved law, which is to provide authorized patients with quality-controlled products in a safe and transparent environment.”
NMM, which spearheaded the state’s legalization effort, is also protesting the regulations, stating Nebraskans exercised their constitutional right by enacting Statute 438 that legalized medical cannabis in all its forms, compelling the Commission to implement it as written. NMM says any attempt to dilute access or restrict parts of the plants is not only unacceptable, but also unlawful.
The Commission is accepting public comments at lcc.frontdesk@nebraska.gov until July 15th, with formal rules for the program to be finalised by October 1st. While the emergency rules can remain in effect for 90 calendar days, they can be renewed for a second 90 calendar day period.
“We encourage all Nebraskans to submit public comment on the proposed regulations, specifically how these regulations prohibit the use of whole-plant cannabis and limit methods of administering the medicine,” NMM says.
NMM had been attempting to get medical cannabis legalised in the state for years. After multiple failed attempts, the issue was finally put in front of the state’s voters last November in two ballot initiatives that passed with more than 70% voting yes. There were further legal challenges, but Governor Jim Pillen signed proclamations that ballot measures 437 and 438 were law in December last year.
A major Massachusetts cannabis testing laboratory was orderedto cease operations Thursday night, following a suspension order from the Cannabis Control Commission, which cited the lab for downplaying the levels of contaminants in the cannabis it tested over the span of a year.
The suspension order, the first ever issued by the commission, alleges that Tyngsborough-based Assured Testing Laboratories failed to accurately report levels of mold and yeast it found in the cannabis it tested. Issued Monday, the order requires Assured — one of the state’s largest cannabis testing labs — to halt operations by midnight July 4.
“The Cannabis Control Commission (Commission) remains vigilant in its efforts to ensure consumers and patients have access to fairly and accurately tested products in the marketplace,” a Commission spokesperson said.
Assured has 21 days to appeal the decision. The company did not respond to requests for comment.
The suspension order marks the commission’s biggest step yet toward cracking down on alleged testing fraud. Cannabis testing fraud can include artificially inflating levels of THC, the chemical that causes a “high,” and underreporting contamination test failures.
Labs that misreport potency and contaminant levels attract growers and manufacturers seeking favorable test results for their products — ultimately allowing cannabis with mold or yeast above the regulatory limit to reach consumers, Globe reporting and data analysis in September showed.
In a lawsuit filed earlier this year, cannabis testing facility MCR Labs alleged eight of its competitors, including Assured, used deceptive practices to attract business by artificially inflating potency and ignoring failed test results for yeast, mold, lead, and pesticides.
“It’s gratifying to see the CCC take decisive action in the space, and we believe that this order moves all labs in the right direction, towards sound science and accountability,” said Yasha Kahn, vice president of marketing and data science at MCR, in a statement.
The Cannabis Control Commission task force found that Assured “established a pattern of failing to accurately report Total Yeast and Mold test results,” according to the order.
On average, about 4.5 percent of the marijuana tested in Massachusetts fails tests for yeast and mold because the levels exceed regulatory limits, according to the order. But from April 2024 to April 2025, Assured reported that just 0.05 percent — 10 out of 17,565 samples — failed tests because of contamination above the regulatory limit.
The commission found Assured’s practices posed an “immediate or serious threat to public health, safety or welfare.” Contaminated marijuana can cause respiratory issues, infections, and other health concerns.
Assured found low levels of yeast or mold — all below the regulatory limits — in about 7,200 samples But the lab reported the levels as zero or undetectable, according to the order.
Assured did not report 544 failures, or samples that had values above the limit for yeast and moldcontamination, according to the order. The commission also found Assured reanalyzed 160 samples multiple times after initial tests indicated contamination above the limit.
During the time period described in the order, Assured processed 22,531 lab samples and performed assessments that included testing for total yeast and mold on 18,246 of them. That represented about 25 percent of all such tests in Massachusetts during that time period, according to the order.
“CPEAR’s poll is a thinly veiled attempt to persuade policymakers to take a broadly popular issue in a less popular direction.”
By Damian Fagon, Parabola Center
In 1994, R.J. Reynolds quietly pumped millions into a flag-waving coalition called “Get Government Off Our Back.” The mission was simple: pose as a grassroots movement with an anti-regulation agenda to prevent the Food and Drug Administration from touching cigarettes. Three decades later, a similar playbook has found its way to cannabis, and the fingerprints are unmistakable.
Today’s vehicle is the Coalition for Cannabis Policy, Education and Regulation (CPEAR), bankrolled in part by Altria, the Marlboro parent that sank $1.8 billion into the cannabis firm Cronos Group. Earlier this month, CPEAR released a poll trumpeting a popular “mandate” for the STATES 2.0 Act, a bill that would take a “states’ rights” approach to marijuana. Set aside the patriotic headlines and the math tells another story. This poll functions not to record public opinion, but to manufacture it.
The Messenger Is The Message
CPEAR is not a neutral think tank. It is a front group financed by Altria and other tobacco and alcohol giants.
The polling firm, Forbes Tate Partners, also happens to be a public affairs firm and a registered lobbyist for Altria. Sponsor and pollster are, quite literally, on the same team.
Accepting the findings at face value asks us to forget that the data and the desired outcome share the same business address.
A Framework For Consolidation
The cynical design of CPEAR’s favored bill, STATES 2.0, lies in what it doesn’t do: expunge criminal records, protect cannabis workers’ rights, prevent marijuana-related deportations or take any accountability for the harms caused by the war on drugs. Instead, 50 states will compete for investment on the most lenient, “business-friendly” terms they can devise.
The deepest-pocketed operators and conglomerates will flock to low-tax, low-oversight jurisdictions, monopolize supply chains and absorb smaller competitors. We have seen this playbook before in alcohol and tobacco, and the economic logic with cannabis will be no different.
Every law we pass shapes the economy Americans will inherit. Adopting the STATES 2.0 Act would codify consolidation and leave mom-and-pop operators scrambling for scraps.
Congress can choose a better course by insisting on a legalization framework that clears records, protects state regulation and channels investment to the very communities that paid the highest price under prohibition. Anything less turns legalization into prohibition by another name.
Persuasion By Design
CPEAR’s poll is a thinly veiled attempt to persuade policymakers to take a broadly popular issue in a less popular direction. It frames STATES 2.0 in the language of states’ rights, a tested appeal to conservative voters, while staying silent on relevant questions related to record expungement, equity and small business access.
And by asking how a person would feel about a congressional candidate or the Trump administration if they supported marijuana reform, the final question seeks to make CPEAR’s chosen bill look like a winning political decision. And yet, it isn’t.
What The Numbers Really Say
The poll’s own data reveal a critical weakness. Despite general support for federal legalization standing steady at 70 percent, respondent enthusiasm drops to the low 60s when presented within the STATES 2.0 framework.
Wouldn’t we expect a federal marijuana bill to garner at least as much support as marijuana legalization generally? But even in a poll framed by the bill’s own advocates, STATES 2.0 is less popular than the cause it claims to represent.
And the news for their favored politicians is even worse—despite CPEAR’s creative description of a “near majority” being more likely to support a pro-cannabis candidate, the big takeaway is that the actual majority would not be more likely to support a pro-cannabis candidate. With tobacco and alcohol conglomerates leading the lobbying charge, can we blame them?
We don’t know what else the numbers showed.
The report relies on a low-transparency online poll of 2,051 respondents and omits key disclosures that make it impossible to verify or replicate. Without information on respondent demographics, such as age, gender identity, race and income or a nuanced look at their political philosophy instead of just party labels, one could easily “cook the books” by oversampling favorable groups and pretending it happened organically.
By withholding these data, along with the weighting methods that the American Association for Public Opinion Research considers basic requirements, the pollsters tell Congress and the voting public to simply trust them. Given their blatant conflict of interest, why should anyone?
Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
I guess, to kind of close, I wanted to kind of offer you to kind of floor to kind of discuss any other kind of upcoming research that you’re trying to get published, or stuff that you’re working on currently, that you can talk about.
Daniela Vergara:
What we did is that we measured the production of in one facility, the production of photo periods and auto flowers, and how much man hours did it take to take care of those? This is in regard to one facility in New York, an indoor facility. So you cannot honestly extrapolate that into, I don’t know, an outdoor facility in Nevada. I don’t think that Well, I don’t know if there are outdoor facilities in Nevada but in any case, you cannot. So it’s very specific.
We did an economic analysis of production and etc. So I think it’s important to show this out there, because I also think that there’s many cannabis companies, especially cannabis companies, that have been working for a while that already have these numbers, and that know how much they’re producing, and man hours and etc., and they have these numbers, but they have it somewhere, right? And they’re not going to share them. Because whenever I show these results, it’s like, ‘well, that is not true, because blah blah’, and it’s like, ‘really, but where are your numbers?’ Show me. Show me your data. So ideally, this would incentivize people to to have a conversation and a more open conversation of, what are you doing, how and how can we improve. So that’s the paper that I hope to publish.
Law enforcement officers exposed and liquidated the criminal group “Krasnobalivski”, which cultivated and traded cannabis, and also distributed psychotropics through messengers. The group “promoted” a business with a monthly income of over UAH 20 million. This was reported by UNN with reference to the Office of the Prosecutor General.
Details
Five members of the organized group have been notified of suspicion of illegal production, manufacture, acquisition, storage, transportation, shipment, sale of narcotic drugs and psychotropic substances throughout the country.
As the investigation found, the Kryvyi Rih drug group “Krasnobalivski” was organized by a 39-year-old previously convicted resident of the capital, against whom indictments are pending in court. Despite this, the man continued criminal activity related to the illegal circulation of narcotic drugs.
The drug group “Krasnobalivski” had an extensive network for distributing drugs throughout all regions of the country. It operated on a strict hierarchy with a clear division of functions – from organizers and coordinators to direct perpetrators.
The accomplices established a full cycle of cannabis production – from cultivation in specially equipped closed laboratories to growing hemp plants in open ground. In one season, they could produce over 500 kg of ready-to-sell drug products. The “goods” were distributed throughout Ukraine, using the services of logistics companies and creating “master-stashes.”
They traded not only cannabis but also psychotropics. Among regular customers, they sold MDMA, alpha-PVP, and cocaine. Monthly, members of the drug group sold up to 5,000 doses of cocaine, earning over UAH 8 million in profit.
To mask the drug business, they created and administered closed Telegram channels, where they accepted retail “orders,” provided geolocations of “stashes,” and communicated with buyers.
Payments for drugs and psychotropics were accepted exclusively on bank cards of straw persons (drops). Part of the funds was transferred to crypto wallets.
The estimated monthly income of the criminal group from drug trafficking exceeds UAH 20 million. The funds received from illegal activities were spent by the suspects on their own needs – elite housing and cars.
During more than 40 searches in Kyiv, Kyiv, Dnipropetrovsk, Odesa, and Cherkasy regions at residences, places of criminal activity, and in vehicles, law enforcement officers discovered and seized almost 90 kg of cannabis, mobile phones, bank cards, “draft” records, cash totaling the equivalent of UAH 2.4 million, 12 cars, and ammunition.
The suspects have been arrested without the right to bail. The investigation is ongoing.
When Brittany Ramsey started experiencing “awful stomach episodes” she thought it must’ve been side effects of the medication she was taking to manage her diabetes.
But after a particularly gruelling episode where she just could not stop vomiting — not being keep down even small sips of water — that landed her in hospital, Ramsey knew something felt different about what she was experiencing.
“From then, the episodes got worse and worse, and closer together,” said Ramsey, a 35-year-old operations trainer at a financial firm in Cincinnati, Ohio. “From 2021 to 2024 … three years, I was hospitalized 29 times. Five ambulance trips – one actually had to pick me up on the side of the road because I couldn’t make it to the hospital.”
After years of undergoing, at times, invasive testing procedures to rule out Crohn’s disease, gastroparesis and diverticulitis, a doctor told Ramsey about cannabis hyperemesis syndrome (CHS).
Brittany Ramsey, who has struggled with CHS for years, at a restaurant, being able to eat normally again for the first time after a long period of debilitating CHS episodes. (Submitted by Brittany Ramsey)
In recent years some emergency rooms have been seeing an uptick in visits due to cyclic episodes of uncontrollable vomiting in cannabis users, often characterized by experiencing temporary relief with hot showers and baths. Since it was first identified in medical literature in 2004, CHS cases have increased, possibly because of greater cannabis access or higher THC potency of products.
Public health researchers suggest more awareness of CHS within the health-care system is needed for cannabis users to get the information and support they need.
More CHS cases in the ER
CHS is characterized by “severe and persistent vomiting” and is usually seen in people who have been using cannabis several times a week for multiple years, said Jamie Seabrook, a professor at the Department of Epidemiology and Biostatistics at Western University in London, Ont.
Ramsey said she’d been smoking at least once a day for over 10 years since she was 18 when she first started experiencing CHS symptoms in 2017.
A 2022 study by researchers at the Ottawa Hospital Research Institute looked at the rate of emergency department visits for CHS after recreational cannabis was legalized and commercialized in Ontario, looking at nearly 13,000 CHS-related hospitalizations in Ontario from 8,140 individuals between 2014 and 2021.
The study, published in the Journal of the American Medical association (JAMA), found that emergency department visits related to CHS had increased by 13-fold over a period of nearly eight years. The study doesn’t show what caused the change, but the authors noted that the biggest increase in visits came not after legalization in 2018 but after Ontario allowed expansion of retail stores in 2020, which coincided with the COVID-19 pandemic.
ER visits related to CHS have increased in Ontario in recent years, according to a 2022 study. (Frank Gunn/The Canadian Press)
Though we don’t have numbers how many people have been diagnosed or hospitalized with CHS, online communities are filled with people looking for support.
Ramsey is part of one of them — a CHS Facebook group described as a “safe place to recover and learn” with 3,000 members. The largest CHS Facebook group has 31,000 members. On Reddit, the group r/CHSinfo has 20,000 members, with discussions ranging from tips on how to manage episodes and personal anecdotes about repeated hospitalizations.
Seabrook, who co-authored a recent review of existing research on CHS in youth, said there’s been an “explosion” of people showing up in some North American emergency rooms with CHS within the last seven to eight years.
The Ottawa Hospital Research Institute study showed that other cannabis-related emergency room visits, including for intoxication and dependence, saw a substantial increase starting in early 2020 as well.
Jamie Seabrook, a professor at the Department of Epidemiology and Biostatistics at Western University, says the wider healthcare system needs more awareness of CHS. (Travis Dolynny/CBC)
Surge in THC potency since the 1980s
Seabrook said a likely reason for increased rates of CHS is the high THC potency of cannabis products today.
THC is the compound in cannabis that is responsible for the sensation of a high most people experience when consuming it. When its potency increases, so do its harmful effects.
Different strains of the plant will have different concentrations of active compounds, measured by percentage of total weight or volume. On average, THC content is much higher today than it used to be.
“The potency of THC was only about three per cent in the 1980s and today, according to Health Canada, the average is 15 per cent with some strains as high as 30 per cent,” Seabrook said, citing Health Canada numbers for “fresh or dried herb material.”
“So we’re talking a 400 per cent or higher increase in the potency.”
Increased THC potency of cannabis products could be a reason behind the higher CHS rates, says Seabrook. (Ryan Remiorz/The Canadian Press)
For “chemically concentrated extracts,” such as hash oil, shatter, budder and wax, the typical potency can be up to 90 per cent, according to Health Canada data.
“The potency, I think, is what’s causing the illnesses to become more and more prevalent, because they’re smoking a lot more potent stuff,” Ramsey said. “And that’s the same with me. When I first started smoking, it was my brother’s homegrown stuff, versus getting it from friends and dispensaries out in California, where it does get stronger and stronger.”
“I feel like maybe before just making marijuana available to the masses, maybe some of these things should have been looked into. You know, too much of anything might be bad,” said Ramsey.
Lawsuit against Aurora Cannabis cites CHS
A lawsuit was recently brought against Canadian cannabis production company Aurora Cannabis for alleged negligence of failing to warn consumers about the potential risk for developing CHS from the regular use of its products. The lawsuit was certified by the Ontario Superior Court of Justice last month, meaning it can proceed as a class action.
Margaret Waddell, the lawyer prosecuting the case, said she hopes that if the lawsuit is successful, it could have an industry-wide effect on including CHS in their product labelling.
“Ideally, Health Canada will require them at some point,” Waddell said. Health Canada does require cannabis manufacturers to warn customers about specified risks — including psychotic symptoms, addiction and dependence — but Waddell said there aren’t currently any requirements to specifically include CHS in those warnings.
Aurora Cannabis declined to comment on the lawsuit, writing in an emailed statement: “It is the company’s practice not to comment on legal matters beyond information that is made available to the public.”
“Information that [CHS] exists is very important,” Seabrook said. “In schools, in health-care settings – whether that’s neurologists, psychiatrists, [emergency room] doctors – and public health campaigns, so people can make a better informed decision about their cannabis use.”
Two men have been charged after police seized suspected cannabis plants with an estimated street value of £1.4m in the Strabane area.
The seizure was made during a planned search operation on Wednesday.
Following the seizure, police said they had dismantled what is believed to have been one of the biggest suspected cannabis operations in the north west in recent years.
The men, aged 28 and 24, are charged with cultivating cannabis, possession of a Class B controlled drug and possession of a Class B controlled drug with intent to supply.
VANCOUVER, British Columbia, July 03, 2025 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (“CLC” or the “Company“) (CSE: CLC) announced today that it will not be filing its annual financial statements, accompanying management’s discussion and analysis and related chief executive officer (“CEO“) and chief financial officer (“CFO“) certifications for the financial year ended February 28, 2025 (collectively, the “Annual Filings“), within the period prescribed for the filing of such documents under Parts 4, 5 and 6 of National Instrument 51-102 Continuous Disclosure Obligations and pursuant to National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, namely within 120 days of year-end, being June 30, 2025 (the “Filing Deadline“).
The delay at CLC is due to the audit taking longer than expected, primarily because of the high level of testing required and the limited availability of staff resources. The Company’s material item on its balance sheet is inventory and biological assets. Given the increased production levels over the past year and the introduction of additional product lines following the Midway acquisition, the process of costing and inventory allocation is taking longer than originally anticipated. Further, the financings completed in connection with the Midway acquisition earlier in 2024 have added to the workload, requiring additional time to ensure accuracy of the financial statements.
CLC is working closely with its auditor DMCL LLP and is making every effort to submit the Annual Filings in a timely fashion and expects to file no later than July 14, 2025, and will issue a news release announcing the completion of such filings at that time.
CLC CEO Mark Aiken stated, “We support the provision of extra time to allow auditors to satisfactorily complete the 2024 audit and ensure that the financial statements are accurate in all respects.”
The Company is providing this default announcement in accordance with National Policy 12-203 Management Cease Trade Orders (“NP 12-203“). The Company has made an application to the British Columbia Securities Commission, as principal regulator of the Company, a management cease trade order (“MCTO“) under NP 12-203 in respect of the default regarding the Annual Filings. The MCTO will prohibit the CEO and the CFO from trading in securities of CLC for so long as the Annual Filings are not filed. The issuance of the MCTO, if issued, does not affect the ability of persons other than the CEO and the CFO of the Company to trade in the Company’s securities. The application for the MCTO remains subject to the risk factors described in “Forward Looking Information and Risk Factors” below, including the risk that the MCTO application may not be successful or may not be completed prior to a securities commission issuing a failure-to-file cease trade order against the Company following the Filing Deadline.
The Company confirms that it intends to satisfy the provisions of the alternative information guidelines found at sections 9 and 10 of NP 12-203 respecting Cease Trade Orders for Continuous Disclosure Defaults for so long as it remains in default as a result of the late filing of the Annual Filings. During the period of default, the Company will issue biweekly default status reports in the form of further news releases, which will also be filed on SEDAR. The Company confirms that there are no insolvency proceedings against it as of the date of this news release. The Company also confirms that there is no other material information concerning the affairs of the Company that has not been generally disclosed as of the date of this news release.
ABOUT CLC
Christina Lake Cannabis is a licensed producer of cannabis under the Cannabis Act. It has secured a standard cultivation license and corresponding processing amendment from Health Canada (March 2020 and August 2020, respectively) as well as a research and development license (early 2020). Christina Lake Cannabis’ facility consists of a 32-acre property, which includes over 950,000 square feet of outdoor grow space, offices, propagation and drying rooms, research facilities, and a facility dedicated to processing and extraction. Christina Lake Cannabis also owns a 99-acre plot of land adjoining its principal site. CLC focuses its production on creating high quality extracts and distillate for its B2B client base with proprietary strains specifically developed for outdoor cultivation to enhance extraction quality.
For more information about CLC, please visit: www.christinalakecannabis.com
This news release contains statements and information that may constitute “forward-looking information” within the meaning of applicable securities legislation, including statements identified by the use of words such as “will”, “expects”, “positions”, “believe”, “potential” and similar words, including negatives thereof, or other similar expressions concerning matters that are not historical facts.
Such forward-looking information is not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information contained herein may include, but is not limited to, information concerning the estimated filing date of the Annual Filings, and whether the British Columbia Securities Commission will grant the Company’s application for an MCTO.
By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. Some of these risks include, but are not limited to, the risk that the Annual Filings are filed later than anticipated, the risk that the Company’s application for an MCTO is not successful for any reason, in which case there is a risk that trading in the Company’s securities may halted by the Canadian Securities Exchange and/or cease traded temporarily by the Canadian securities commissions after the Filing Deadline until such time as the Annual Filings are filed on SEDAR.
Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
In connection with the forward-looking information contained in this news release, the Company has made certain assumptions. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information contained in this news release are made as of the date of this news release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this notice.
